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The  induction,  in  vitro,  of human  antibody responses to non-MHC ~ (major 
histocompatibility complex) antigens  has been described for only a  few soluble 
protein antigens,  including tetanus toxoid (1), influenza virus proteins (2), and 
keyhole limpet  hemocyanin  (3).  In  contrast,  the  in  vitro  induction  of human 
antibodies specific to carbohydrate antigens has not been systematically analyzed. 
Responses  to  carbohydrate  determinants  are  involved  in  the  defense  against 
bacterial infections, parasites, and perhaps in the recognition of tumor-associated 
antigens (4).  As a model for studying the human anticarbohydrate response and 
its regulation in vitro, we chose the response to the group-specific carbohydrate 
(A-CHO) of A streptococci (Strep A), for the following reasons: (a) Remarkable 
amounts of anti-A-CHO antibodies were found in sera of most human adults (5, 
6,  7)  suggesting  a  ubiquitous  anamnestic  response  in  the  human  population. 
Therefore, in vitro studies do not require artificial immunizations.  (b) The anti- 
A-CHO response in rabbits and in mice has been extensively analyzed both in 
vivo and in vitro (8-10).  Beside the knowledge on specificity and heterogeneity 
of T  and B cells involved in this response, these studies provided information on 
immunoregulation  by  idiotype-antiidiotype  interaction  (11),  on  which  future 
experiments in the human system might be based. Cross-reacting and dominant 
idiotypes have now been characterized for human anti-A-CHO antibodies (12). 
(c) A-CHO and  its immunodominant  hapten  N-acetyl-D-glucosamine (GIcNAc) 
are structurally well characterized (15). Even the three-dimensional structure of 
A-CHO was recently revealed (D. Bundle,  National  Research Council, Ottawa, 
personal communication). (d) A large number of experiments, including studies 
on A-CHO-specific antibodies  from  man,  mouse, and  rabbits demonstrated  a 
restricted  clonal  heterogeneity  and  a  pronounced  clonal  dominance  for  this 
response (7, 8,  10);  this situation may facilitate precursor frequency analyses of 
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B cell clones. (c) The anti-A-CHO response requires cooperation with regulatory 
T  cells (14). 
We report here that (a) in sera of randomly selected, healthy human individuals 
without anamnestic rheumatic fever, proportions of > 10% A-CHO-binding IgM 
or IgG are found that are mainly directed to GicNAc. (b) Antibodies produced 
in vitro are predominantly of the IgM isotype, independent of whether they are 
produced by polyclonai or by antigen-specific activation. This is in contrast to 
the anti-A-CHO antibodies produced in vivo, and to in vitro-produced antibod- 
ies of other specificities that contain substantial proportions of IgG. Therefore, 
anti-A-CHO antibodies appear to be produced by B cells that may represent a 
functionally distinct subpopulation.  (c)  The  proportions of IgM  anti-A-CHO 
found in serum and in activated macrocultures are paralleled by equivalent B 
cell precursor frequencies for IgM anti-A-CHO in peripheral blood lymphocytes 
(PBL), suggesting that the IgM-producing B cell precursors are equally frequent 
in peripheral blood and in the antibody-producing lymphoid tissues, with a mean 
IgM production rate not exceeding the mean of the entire B cell pool. 
Materials and Methods 
Cell Separations.  Human peripheral  blood mononuclear cells from healthy volunteers 
were  obtained  from  Ficol]/metrizoate  density  gradients  (1,077  g/cm  3)  in  a  standard 
procedure (15). B cells were prepared by rosetting T cells with 2-aminoethylisothiouron- 
ium bromide hydrobromide (AET) (Sigma Chemical Co., St. Louis, MO)-treated sheep 
red  blood  cells followed  by  a  Ficoll/metrizoate  gradient (16). The  B  cell-enriched 
population  was collected from the interphase,  containing  50-70%  Ig  + cells, <8% T3 + 
cells, as revealed by peroxidase-antiperoxidase and fluoresence staining (cytofluorometric), 
and 20-40%  monocytes positive for 0-naphtyl-acetate-esterase. In the T  cell-enriched 
population, sheep red blood cells were removed by hypotonic lysis with distilled water at 
4°C for 20 s. 
Antigen Preparation.  For vaccine preparation,  group Strep A, strain 17A4, were heat- 
killed and cleaved from their protein coat by pepsin treatment, as described (17). The 
concentration of organisms  was adjusted by counting in  a  hemocytometer chamber. 
Group-specific carbohydrates  of Strep A and C (strain C74) were prepared by NaNO2/ 
acetic acid extraction (E. C. Gotschlich, personal communication). Briefly, 8 g streptococci 
cultured in Todd-Hewitt broth were suspended in 80 ml Aqua bidest. 10 mi 4 NNO~ and 
10 ml acetic acid were added, and the suspension was stirred for 15 min. Detritus was 
centrifuged at 15,000 gmax for 10 rain and the SUP (supernatant), containing the group- 
specific carbohydrate, was extensively dialysed against distilled water, and lyophilized. For 
coupling  to plastic sites, the carbohydrates  were esterified  with stearic acid (18). The 
monosaccharides,  GlcNAc and N-acetyi-~galactosamine  (GalNAc), used  for inhibition 
studies, were purchased from Sigma Chemical Co. 
Antibodies.  Antibodies reactive to GIcNAc were isolated from human sera as described 
(19), by absorption on GIcNAc-agarose columns, and subsequently eluted by 5% GicNAc. 
They were separated into the IgM and IgG fractions by high-pressure liquid chromatog- 
raphy on a TSK 3000 column (LKB Instruments,  Inc., Gaithersburg  MD). 
F(ab')2 and Fab' fragments wereDprepared as described (12). A goat antiserum specific 
for human % a, and # chains was precipitated  by ammonium sulfate and used in solid- 
phase enzyme-linked immunosorbent assays (ELISA). Reference sera adjusted to World 
Health Organization (WHO) standards for human IgM and IgG (Behringwerke, Marburg, 
Federal  Republic of Germany [FRG]) were purchased.  Goat anti-human IgM and goat 
anti-human IgG labeled with alkaline phosphatase were obtained from Medac (Hamburg, 
FRG). 
Culture Conditions.  Cultures  for the determination of SUP Ig production were per- 
formed either in the original  MishelI-Dutton conditions (20), with the modification of EMMRICH  ET  AL.  549 
using Dulbecco's modified Eagle's medium supplemented with 2-mercaptoethanol (10  -5 
M,  final  concentration),  sodium  pyruvate  (0.11  g/liter)  L-asparagine  (0.036  g/liter), 
penicillin (100  U/mi), streptomycin (100 #g/ml) and  10%  fetal calf serum (FCS);  or in 
Click's medium (21)  supplemented with penicillin,  streptomycin, and  10%  FCS at  2% 
CO2, without rocking. 
Polyclonal and Antigen-specific In Vitro Activation  of Human Lymphocytes.  For polyclonal 
activation,  1.5  ×  106 human PBL were cultured in l-mi flat-bottom wells (Nunc GmbH, 
Wiesbaden,  FRG) together with pokeweed mitogen (PWM) in a  1:200  final dilution of 
the stock solution (Gibco Laboratories, Grand Island, NY). Some experiments were carried 
out with cryopreserved human PBL. Previous cryopreservation did not alter the yield of 
antibodies produced in culture, nor the B cell frequencies determined by limiting dilution 
(F.  Emmrich, unpublished observation). Antigen-specific activation was achieved by in- 
cubating 2 ×  105 unseparated PBL per well together with heat-killed, pepsin-cleaved Strep 
A  in  200-#1  round-bottom  microtiter wells  (Nunc  GmbH). The  microorganisms were 
titrated as indicated. Culture supernatants were tested by solid-phase ELISA for various 
antibodies produced during the culture period. Antibodies appear in measurable amounts 
generally on day 4  and reach a  plateau between days 8 and  12.  By the cell separation 
procedure described above, no carry over of cytophilic Ig was observed that exceeded 
our sensitivity threshold of 100 pg/ml. Culture SUP harvested at day 12 by centrifugation 
were stored at -20 °C in microtiter plates until assay. 
Antibody Assays.  Solid-phase ELISA were performed essentially as described (19) for 
the determination of anti-A-CHO antibodies as well as for the determination of total IgM 
and IgG in cell culture SUP.  Human IgM anti-A-CHO or IgG anti-A-CHO reference 
preparations of a  human serum pool (10 sera of healthy blood donors) were diluted  in 
culture medium, and a seven-point duplicate standard dilution curve, ranging from 0.26 
to 4,000 ng/mi, was set up on each assay plate. In general, plates were measured after 30 
rain, 2 h, and 24 h by an automatic photometer (MR-580; Dynatech Laboratories, Inc., 
Alexandria, VA) in order to find high as well as low test values in sensitive regions of the 
shifting standard  curve.  Standard  curves  were calculated  and drawn  by an  Applesoft 
BASIC program (SPLINE 4) which uses spline functions to find an optimal nonlinear 
standard curve for calculating Ig concentrations. 
For inhibition studies, soluble carbohydrates or monosaccharides were added in various 
concentrations, as indicated in Fig.  1, to culture SUP containing anti-A-CHO antibodies, 
or to purified reference antibodies, before incubation of antigen-coated microtiter plates. 
Determination  of B Cell Precursor Frequencies.  B cell precursor frequencies for IgM or 
IgM anti-A-CHO-producing cells were determined by limiting-dilution analysis of repli- 
cate microcultures. Varying numbers of AET-rosette-negative cells in log~ dilution steps 
were cultured on  105 unseparated or T  cell-enriched PBL irradiated with 3,000 rad in 
96-well round-bottom microtiter plates in a final volume of 0.2 ml Click's medium with 
10%  FCS  containing  PWM  (1:200)  as polyclonal activator.  20  replicate cultures  were 
established for each dose of B cells, ranging from 2 ×  105 to 40 cells in the experiments 
5  5  described. In culture wells with 2 ×  10  and 1 ×  10  cells, the amount of feeder cells was 
reduced to 5  ×  104. As mentioned above, the rosette-negative population includes 30- 
50%  non-B cells,  so that the determined B cell frequencies are underestimated  up to 
100%. For control, five wells with no added B cells and five wells with 2 ×  104 irradiated 
B cells were included in each culture plate, containing, in general, three culture groups. 
After 12 d the culture SUP were harvested and stored until antibody assay. Those wells 
with more Ig than the arithmetic mean plus three standard deviations of the controls were 
scored as "positive", and the fraction of negative wells was calculated for each B cell dose. 
Poisson analysis was used to determine the precursor frequency for Ig-producing cells 
(for theory, see reference 22) by plotting the number of cells against the proportion of 
negative wells within each test group. Frequencies were calculated by an iterative program 
(MINCHI), written  in  Applesoft,  which  provides four mathematically different  fitting 
approaches. The minimum X  2 method was selected according to Taswell (23), considering 
his criteria that beside P  >  0.05, the frequency determined by minimum X  2 should stay 
within 4-15% of that determined by the maximum likelihood method. 550  HUMAN  IMMUNE  RESPONSE  TO  A-CHO 
TABLE  I 
A-CHO-specific Antibodies and Total lg in Human Sera of Individual Donors and in Culture 
SUP of Their Polydonally Activated Lyraphocytes 
Material  Donor 
IgM 
Ig concentration* 
IgG  IgM anti-  IgG 
A-CHO  anti-A- 
CHO 
Serum or plasma 
Culture supernatant* 
gg/ml 
HZO  1,400  8,020  77  760 
HTA  3,800  17,600  55  226 
MSS  2,540  11,900  332  230 
BGI  1,340  8,010  18  157 
CMR  2,200  1,130  20  6 
JEN  1,700  7,200  26  71 
RRA  2,000  9,080  36  78 
BMR  1,500  13,100  91  590 
ng/ml 
HZO  4,660  10,109  1,362  62 
HTA  5,092  6,068  183  20 
MSS  6,290  12,222  978  15 
BGI  1,827  2,607  35  2 
CMR  3,825  1,367  397  1 
JEN  3,297  1,558  16  2 
RRA  1,589  1,455  65  4 
BMR  15,835  15,750  1,722  6 
* lgM and IgG in serum or plasma were determined by radial immunodiffusion using WHO-proved 
standards.  IgM and  IgG in culture SUP were determined in solid-phase ELISA by means of the 
same standards. IgM anti-A-CHO and IgG anti-A-CHO were measured in serum as well as in SUP 
by ELISA using as standards affinity-purified, HPLC-separated preparations of specific antibodies 
diluted in culture medium containing FCS. 
* Polyclonal activation was carried out in 1-ml flat-bottom wells by culturing 1.5 x  106 mononuclear 
lymphocytes with PWM (1:200) for 12 d in Click's medium with 10%  FCS at 2% COs. 
Results 
Quantities of Total IgM and IgG, and of A-CHO-specific lgM and IgG Produced 
In Vivo and by Polyclonal Activation In Vitro.  We studied seven randomly chosen 
healthy adults in these experiments, as well as one donor (MSS) specially selected 
because of a major GIcNAc-binding antibody spectrotype in his serum (12). We 
determined IgM and IgG concentrations by radial immunodiffusion, whereas we 
measured IgM anti-A-CHO and  IgG anti-A-CHO concentrations by a  solid- 
phase ELISA. For comparison, PBL of these donors were stimulated in vitro by 
PWM, and after 12 d, total Ig and specific Ig were measured in the cell culture, 
also by solid-phase ELISA. A compilation of these results appears in Table I. We 
prepared the reference antibodies used as standards for the ELISA assay from a 
pool  of 10  human sera;  they represent average avidity spectra as judged by 
comparing their binding curves with that of individual antibody preparations 
(data not shown). Strikingly high proportions of total IgM and IgG of all donors 
bound to A-CHO, ranging from 1.0 to  13.1%  for IgM anti-A-CHO and from 
0.5  to  9.5%  for IgG anti-A-CHO in serum. In culture SUP,  we found high 
proportions of anti-A-CHO (0.5-29%)  for IgM but not for IgG (0.07-0.6%) EMMRICH  ET  AL.  551 
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Fine specificity  analysis  ofanti-A-CHO produced after polyclonal  B cell activation 
in vitro (A) compared with affinity-purified  anti-GlcNAc IgM adjusted in culture medium to 
the same antibody concentration (B). IgM anti-A-CHO was measured by a solid-phase ELISA 
using stearoyI-A-CHO as antigen, and  an  enzyme-labeled anti-human IgM as detection 
reagent. 
(Table I),  The ratio of IgM anti-A-CHO to IgG anti-A-CHO ranged from 0.1 
(donor HZO) to 3.3 (donor CMR) in serum, whereas, in strong contrast, in vitro 
polyclonally activated  PBL produced  mainly  IgM  anti-A-CHO  with  IgM/IgG 
ratios of 8  (JEN) and  397  (CMR) to one.  The deficiency in  IgG anti-A-CHO 
production was not a consequence of a deficiency in the total IgG production in 
vitro, because total IgM/IgG ratios were, in most cases, only slightly lower than 
in serum. 
Fine Specificity of Anti-A-CHO Antibodies Produced In Vitro.  A-CHO-specific 
antibodies  in  sera of immunized  animals  (24) or of human  donors  (7) consist 
mainly of antibodies to GIcNAc, the immunodominant group of the A-CHO. To 
analyze the fine specificity of anti-A-CHO antibodies produced in vitro we used 
various mono- and polysaccharides. They were tested for their ability to inhibit 
the binding to solid-phase A-CHO of anti-A-CHO antibodies in culture SUP of 
polyclonally activated PBL (Fig.  1). This was compared with the affinity-purified 
IgM  anti-GlcNAc  preparation  from  the  serum  of the  same  individual,  after 
adjusting  to a  similar  Ig concentration  as  the  antibody  produced  in  vitro.  A- 
CHO and  its monosaccharide hapten  GicNAc inhibited  both antibody popula- 
tions, whereas we saw no inhibition  with the carbohydrate of C-streptococci (C- 
CHO), which carries N-acetyl-D-galactosamine (GalNAc) disaccharide side chains 
instead of GIcNAc on the same rhamnose  backbone (13).  As usual,  inhibitions 
with the monosaccharides required higher inhibitor concentrations than with the 
complete carbohydrate molecule.  From these results, we conclude that,  similar 
to antibodies produced in vivo, most anti-A-CHO antibodies produced in vitro 
are directed to GIcNAc. 
Determination of  B Cell Precursor Frequencies  for IgM and IgM Anti-A-CHO.  To 
study whether the high proportions of A-CHO-specific IgM in vivo and in vitro 
were reflected in  PBL with an  equally high  proportion  of B cells of the same 
specificity, we did the following experiments.  We determined the frequencies of 
IgM-producing  B  cells and  the  frequencies of B  cells that  produce  IgM anti- 552  HUMAN  IMMUNE RESPONSE TO  A-CHO 
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FIGURE 2.  Precursor  frequency analysis of Ig-producing cells after polyclonal activation. 
Human B cells from donor MSS were enriched by rosetting with AET-treated sheep red blood 
cells. The rosette-negative population was added in twofold dilutions (2 x 105-40 cells/culture) 
to round-bottom microtiter wells (20 wells/group) containing 10  ~ irradiated autologous PBL 
and 1:200 PWM as polyclonal  activator. After 12 d, culture SUPs were collected and measured 
for lgM (l~""-Q) and for anti-A-CHO  IgM (A  A). Mean Ig values plus three SD of 
cultures  with  2  x  104  irradiated  B cells were  used as  thresholds  for negative cultures. 
Frequencies of antibody-producing cells and SD were calculated according to Poisson  statistics 
by a computer program on the base of the minimum X  2 procedure. The hatched area refers 
to the 95% confidence interval. 
A-CHO by limiting dilution analyses using B cell-enriched PBL. We chose three 
donors (MSS, HTA, JEN) with high, intermediate, and low proportions, respec- 
tively, of IgM  anti-A-CHO  antibodies after polyclonal activation in  macrocul- 
tures (see Table  I).  Fig.  2  shows a  representative experiment. By plotting cell 
numbers versus the log of the fraction of negative cultures, we obtained straight 
lines in all cases, demonstrating single-hit kinetics, which allows the calculation 
of precursor frequencies (22). All frequencies are minimum estimates because of 
the contamination by non-B cells. In order to obtain correct ratios, we adjusted 
the detection limits of the assays (used for both IgM and IgM anti-A-CHO)  to 
equivalent sensitivities.  Proportions of IgM anti-A-CHO-specific B  cells (abso- 
lute frequencies) were calculated by dividing their precursor frequencies by that 
of IgM-producing cells. 
Table II gives B cell precursor frequencies for IgM and for IgM anti-A-CHO EMMRICH  ET  AL.  553 
TAnLE II 
Determination of  B Cell Precursor Frequencies  for IgM and lgM Anti-A-CHO After Polyclonal 
Activation With PWM 
Donor 
Precursor frequency*  IgM anti-A-CHO/lgM  ratio 
lgM  IgM anti-A-CHO  4,  ~  Macrocul-  turet  Serum! 
MSS 
HTA 
JEN 
% 
Exp. 1  1:4,272  (1:3,137-1:6,693)  1:22,727 (1:16,393-1:37,037)  18.8  15.5  13.1 
Exp. 21  1:173  (1:129-1:266)  1:974  (1:739-1:1,456)  17.8 
1:279  (1:186-1:564)  1:6,361  (1:4,744-1:9,653)  4.4  3.6  1.4 
1:119  (1:90-1:176)  1:37,175  (1:13,072-1:51,546)  0.3  0.5  1.5 
* Results in parentheses limit the 95% confidence intervals. 
$ Percentages calculated from the precursor frequencies in PWM-activated microcultures, using the results from this table. 
! Percentages calculated from the IgM anti-A-CHO and IgM concentrations of PWM-activated macrocultures given in Table I. 
I Percentages calculated from serum lg concentrations given in Table I. 
Exp. 2 of donor MSS is shown in Fig. 1. For experimental details see legend of Fig. I. 
from donors MSS, HTA, and JEN. For comparison, ratios of soluble antibodies, 
calculated from polyclonally activated macrocultures and from antibody deter- 
minations in serum, are included. Within the reproducibility of the assays, we 
obtained the same proportions from all three calculations, for each donor. This 
suggests  that  (a)  B  cell  precursors  for  IgM  anti-A-CHO  are  nearly equally 
frequent in PBL and in the lymphoid tissues; and (b) the mean IgM anti-A-CHO 
production per B cell  is similar to  the mean IgM production of all  B cells in 
vitro. 
Two of five experiments for donor MSS are shown in Table II, representing 
the highest (1:173) and lowest (1:4272) frequency of IgM-producing cells. This 
pronounced experimental variability is primarily due to variation in the efficiency 
of PWM  activation.  In  spite  of this  variability,  we  found  the same absolute 
frequencies of IgM anti-A-CHO-producing B cells in the experiments with the 
lowest and highest efficiency of mitogen activation. 
In agreement with other groups, <1% of all human peripheral blood B cells 
are activated by PWM (25, 26), in contrast to mouse B cells, of which 30% may 
be activated polyclonally (27). In view of the low percentages of B cells activated 
by PWM, and the high proportion of A-CHO-specific B cells among them, we 
suspected  that  PWM  preferentially  stimulated  A-CHO-specific  B  cells.  We 
determined IgM anti-A-CHO/total IgM ratios, using different polyclonal acti- 
vation conditions. We had previously found that, under Mishell-Dutton condi- 
tions at high cell densities (106 cells per round-bottom microtiter well), sponta- 
neous polyclonal activation occurs, resulting in IgM production >20-fold greater 
than that of the same number of PBL cultured in the same volume, with the 
same FCS, in fiat-bottom wells.  PWM does not substantially increase IgM pro- 
duction when added to such high-density cultures. For cells from donor MSS, 
the proportions of IgM produced by high-density activation that had specificity 
to A-CHO ranged from 6.2 to 33.3% (mean, 15.8%) in six independent cultures, 
and thus are similar to the data shown in Table II for PWM activation of PBL 
from MSS. Preferential PWM activation of IgM anti-A-CHO-producing B cells 
is therefore unlikely. However, in cultures without antigen or mitogen, at low 
cell densities, the proportion of IgM anti-A-CHO is very much smaller than in 554  HUMAN IMMUNE RESPONSE TO  A-CHO 
TABLE III 
lgM Anti-A-CHO Proportions in Cultures With Varying Cell Density and Different Activation 
Conditions 
Culture  PBL (×10 5)  Activation  well  lgM  IgM anti-A-CHO  IgM anti- 
A-CHO 
ng/ml  ng/ml  % 
1.5  --  F  507 +  35  5 +  4  1.0 
1.5  Strep A  F  480 +  56  78 4- 30  16.3 
2  --  R  1,020 4- 220  25 4- 9  2.5 
2  Strep A  R  1,330 4- 370  200 4- 170  15.0 
10  --  R  4,508 +  1354  713 4- 512  15.8 
2  PWM  F  6,200 4- 852  775 4- 334  12.5 
Varying numbers of PBL (donor MSS) were cultured for  12  d  with  10%  FCS in either round- 
bottom (R) or in flat-bottom (F) microculture wells (200 #1) with mitogen (PWM 1:200) or antigen 
(Strep A),  or without an addition.  IgM and  IgM anti-A-CHO were determined by solid-phase 
ELISA. 
cultures with either high density, or mitogen- or antigen-induced activation. This 
is shown in Table III for donor MSS, and in the control cultures of Table IV 
for donor CMR. We think that under these in vitro conditions, only those B cells 
that had been preactivated in vivo by unknown antigens secrete IgM. Alterna- 
tively, B  cells specific for FCS components might be preferentially stimulated 
under these culture conditions. 
We also considered the remote possibility that A-CHO binding occurs via the 
constant part of IgM, particularly in the case of donor MSS whose IgM contained 
15%  A-CHO-binding antibodies.  However, using Fab'  fragments of affinity- 
purified  IgM  anti-GicNAc antibodies  from that  donor,  we  found binding  to 
solid-phase A-CHO at levels similar to those seen with the complete molecule. 
Both antibody preparations bound specifically to A-CHO only, and not to the 
closely related carbohydrate of group C streptococci (data not shown). 
Induction  of a  Specific  In  Vitro Response  to  Strep A  Carbohydrate.  Among a 
variety of culture systems, we found that the original Mishetl-Dutton procedure 
(20) with Mishell-Dutton medium, rocking platform, and the special gas mixture 
(10%  CO2,  7%  02,  83%  N2),  and the Click's system (21),  provided adequate 
conditions  for  the  specific  induction  of anti-A-CHO  antibodies.  Specific re- 
sponses could be induced only by the bacterial particles, and not by the soluble 
A-carbohydrate  (data  not  shown).  Fig.  3  shows  IgM  anti-A-CHO  antibody 
concentrations among  PBL  from five donors,  stimulated by various doses of 
Strep A  vaccine. Only in these donors (CMR,  MSS, and HTA) could anti-A- 
CHO antibody secretion be enhanced, with a peak response at 2  ×  10 ~ to 2  × 
104 streptococcal particles per microculture. It should be noted that values of 
individual  culture  wells  varied  far  more  than  observed  in  PWM-stimulated 
cultures.  This  may  indicate  that,  for  specific  activation,  spatial  relationships 
between cooperating cells might be  important.  In some donors,  especially in 
donor  MSS,  IgM  anti-A-CHO  antibodies  were spontaneously produced to  a 
considerable extent. This phenomenon was not caused by cytophilic antibodies, 
because cultures harvested immediately after being established were consistently 
negative for anti-A-CHO antibodies. EMMRICH  ET  AL.  555 
TABLE  IV 
Proportions of  A-CHO-specific Antibodies and Total Ig in Individual Microcultures of  PBL 
Cultured With Various Quantities of Enzyme-cleaved Strep A 
Strep A/culture  Antibody 
Ig concentration in well: 
A  B  C  D 
ng/ml 
IgM  2,600  1,050  1,900  1,050 
IgG  800  140  250  380 
IgM anti-A-CHO  4  3  8  5 
lgG anti-A-CHO  *  --  1  * 
IgM anti-C-CHO  6  6  12  7 
2×  102 
2,200  900  12,200  500 
600  210  2,600  190 
160  8  521  302 
4  *  4  -- 
6  6  400  21 
2 ×  103 
2,500  2,800  18,000  1,200 
360  500  8,000  270 
92  776  299  105 
*  --  11  * 
5  21  134  18 
2×  104 
16,000  1,350  18,100  3,000 
1,500  300  6,300  1,200 
4,868  1,265  ~422  1,042 
8  *  6  * 
17  10  400  56 
2×  105 
460  2,050  4,200  670 
80  360  2,600  120 
4  210  18  34 
*  *  l  * 
3  40  9  4 
2 ×  106 
1,500  2,000  2,100  980 
240  290  980  110 
8  5  15  4 
*  1  1  * 
11  7  18  3 
2×  l0  T 
16,500  4,200  8,200  1,450 
44,000  800  4,200  460 
36  13  14  7 
*  1  2  2 
1  10  19  6 
2 ×  105 PBL (from donor CMR) were cultured for 12 d  in round-bottom microtiter wells with or 
without Strep A ranging from 2 ×  102 to 2 ×  10  ~ Strep A particles per culture. Concentrations of 
specific antibodies and total IgM and IgG were determined by ELISA using 40 #1 undiluted culture 
supernatants for the measurement of specific antibodies and 1:10 dilutions for IgM and IgG. A, B, 
C, and D  represent single culture wells. IgM anti-A-CHO concentrations above 500  ng/ml are 
italic. Ig concentrations within the bending portion of the standard curve are represented by: (*) 
0.3-1.0 ng/ml; (--) <0.3 ng/ml. 556  HUMAN  IMMUNE  RESPONSE  TO  A-CHO 
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FIGURE  3.  Anti-A-CHO  IgM  concentrations  determined  after  12  d  in  cultures  (Click's 
medium,  10%  FCS,  round-bottom  microtiter  wells)  of  PBL  from  five  different  donors, 
incubated  with various amounts  of Strep A  per culture:  medium  control (0),  2  x  10 ~ (2),  2  x 
10 3 (3),  2  x  10  4 (4),  2  ×  10 5  (5),  2  ×  10~  (6),  2  x  l0 T (7).  Each  dot  represents  a  single 
microculture  well. 
To demonstrate that the increase of anti-A-CHO antibodies was not a part of 
a polyclonal increase in total IgM, we performed the experiment shown in Table 
IV. Concentrations of various antibody populations were determined independ- 
ently  in  cultures  stimulated  with  six  different  streptococcal  concentrations. 
Production of A-CHO-specific  IgM was stimulated best at 2  x  104 Strep A  per 
culture. Elevated total IgM was found in two cultures of this group, whereas the 
other  two cultures  showed  normal  IgM  levels.  The  mean  percentages  of IgM 
anti-A-CHO  were 0.33 -¢- 0.13% in the medium controls, and 21.3 _+  13.1%  at 
2  x  10 4  Strep  A  ceils/well,  corresponding  to an  increase  in  specific  antibody 
~60-fold greater than that of total IgM. Independent of the considerable amount 
of IgG produced in most wells, nearly no IgG anti-A-CHO  was found, which is 
in agreement  with the results of polyclonal activation.  Not consistently,  but in 
some wells of the groups at 2 x  102 to 2 x  104 Strep A cells/well,  IgM antibodies 
against streptococcal C carbohydrate were also found. 
At high antigen concentrations (>2 x  106 Strep A cells/culture), only low IgM EMMRICH  ET  AL.  557 
anti-A-CHO  production  was observed.  The possibility that  large amounts of 
streptococci in the culture could absorb the specific antibody was excluded by a 
4-d pulse immunization of cultures, with subsequent removal of the bulk of Strep 
A. After an additional 8 d  of culture, a similar depression of the responses was 
observed for cultures that had been pulsed with high amounts of streptococci, 
and in control cultures in  which the streptococci were present for the whole 
culture period (data not shown). In contrast, as demonstrated in the last row of 
Table IV (culture A), total IgM and IgG were sometimes elevated in cultures 
containing high amounts of Strep A (>2 X 107 Strep A cells/culture), suggesting 
a moderate polyclonal activation by Strep A vaccine at high concentrations. 
Discussion 
In recent studies on quantitative determinations of total anti-A-CHO antibod- 
ies in  human sera (in which no distinction was made between IgM and IgG), 
concentrations of 20-250  gg/ml anti-A-CHO were reported for 30 randomly 
selected healthy donors (28).  In contrast,  in a  group of 12  patients suffering 
from acute rheumatic fever, 70-660 #g/ml anti-A-CHO (29) were found. These 
studies used anti-A-CHO from hyperimmunized rabbits as reference antibody 
for quantitative determinations, measured in a  fluid-phase radioimmunoassay. 
Because of a possibly higher average affinity of the oligoclonal rabbit antibodies, 
and because low-affinity human antibodies might be missed in the fluid-phase 
assay, the serum concentrations of anti-A-CHO, which are presumably of low 
average affinity, might have been underestimated in those studies. This might 
also explain why no  IgM anti-A-CHO  could be detected in human sera in a 
previously published survey (7). 
To circumvent these problems, we used human IgM and IgG that had been 
taken from pooled serum and affinity-purified on A-CHO columns as reference 
for  solid-phase  ELISA  measurement of specific  antibodies.  In  eight  healthy 
donors we found 26-837 #g/ml total anti-A-CHO. The accuracy of the results 
was  confirmed  by  independent  experiments.  For  instance,  we  could  elute 
amounts of anti-A-CHO from A-CHO affinity columns as were predicted from 
serum determinations. This eluant was immunoelectrophoreticaily  pure IgM and 
IgG (data not shown). Furthermore, for IgM, the proportions of anti-A-CHO 
in serum titers were reflected in the proportions of precursor B cells found in 
limiting dilution analyses (Table II). Therefore, proportions of A-CHO-specific 
antibodies comprising >10% of the total IgM or IgG appear not to be unusual 
even in healthy human individuals without a  history of anamnestic rheumatic 
fever or frequent tonsillitis. 
These antibodies are mainly of GIcNAc specificity and are restricted predom- 
inantly  to  the  IgG2/K  isotype  (7).  Anti-GlcNAc  antibodies  may  have  been 
induced not only by A-CHO, but also by other bacterial polysaccharides contain- 
ing terminal GIcNAc moieties in a  1,3-glycosidic linkage, such as the O substance 
of  gram-negative bacteria (30). Moreover, terminal GIcNAc is exposed transiently 
during synthesis or degradation of blood group substance (P. Hanfland, personal 
communication) and might act as an antigenic stimulus. We think, however, that 
the functional significance of the large amounts of anti-GicNAc antibodies in 
healthy individuals lies in the persistance of streptococci in human tonsils without 558  HUMAN  IMMUNE  RESPONSE  TO  A-CHO 
any symptoms of tonsillitis.  It is possible that the immune system prevents an 
overgrowth of these bacteria by maintaining a potent state of natural immunity. 
Varying antibody levels in individual donors may be due to genetic control, as 
demonstrated for rabbit  (31,  32) and mice (33),  as well as different levels of 
continuous challenge by the bacteria. 
All human adults seem to be primed to Strep A, as revealed by an analysis of 
sera from -200 healthy blood donors that contained IgM anti-A-CHO in varying 
amounts. Two cord-blood sera, on the other hand, showed a total lack of IgM 
anti-A-CHO, while containing IgG anti-A-CHO, presumably from the mother. 
In  addition,  we  could  not  induce  IgM  anti-A-CHO  secretion by  polyclonal 
activation (PWM) of human cord-blood iymphocytes (F.  Emmrich, unpublished 
experiments). Together, both experiments indicate the lack of priming in the 
newborn, and an acquired state of natural immunity in adults, as corroborated 
by previous experiments (5). 
In  view of the large amounts of anti-A-CHO antibodies in  sera,  it seemed 
interesting to evaluate, for comparison, the frequency of specific precursor B 
cells in PBL after polyclonal activation by PWM. Essentially similar proportions 
of IgM anti-A-CHO within total IgM were found in serum, SUP of macrocul- 
tures, and, by limiting dilution analyses of B cell precursors, in human peripheral 
blood, the latter amounting to  1/6-1/300  of all IgM-producing B cells. These 
results suggest a similar distribution of those B cells in lymphoid tissues and in 
peripheral blood, and also a similar mean IgM production rate when compared 
with the entire B cell pool. 
Using well-established culture conditions,  we could  induce lymphocytes of 
some adult individuals to  give an  A-CHO-specific response.  This response is 
somewhat erratic, and shows large variations between identical culture wells, 
which, in our hands, is not the case for in vitro secondary responses to tetanus 
toxoid  (a  model  for a  soluble  protein  antigen).  This  suggests  rather  limited 
requirements for the induction of an anti-A-CHO response that are not only 
dependent on the number of available precursor B cells (see donor BMR, Table 
II  and  Fig.  3).  At  high  vaccine  concentration  (>106  Strep  A  cells/culture), 
diminished specific IgM anti-A-CHO levels were observed. This phenomenon 
was not due to absorption of the anti-A-CHO by large amounts of streptococci 
(see comment to Table IV), and may therefore reflect a specific suppression that 
is also observed in secondary in vitro responses to high antigen doses of soluble 
protein antigens (34, 35). Taken together, we think that not all of the regulatory 
factors that influence a  specific anti-A-CHO response in vitro are sufficiently 
understood. 
In PBL obtained from Strep A-immunized rabbits, IgM anti-A-CHO, as well 
as IgG anti-A-CHO, plaque-forming cells were induced in an in vitro secondary 
response, with the latter reaching 83% of the antigen-specificplaques after 15 d 
of culture  (36).  Concomitant secretion  of IgG  anti-A-CHO  into  the  culture 
medium was shown. In contrast, we found nearly exclusively anti-A-CHO of the 
IgM isotype, in both antigen-activated or mitogen-activated human PBL cultures. 
Although slightly less IgG-secreting B cells are activated in vitro than expected 
from  the  IgM/IgG  isotype  proportion  in  serum  (see  Table  I),  total  IgG  in 
polyclonally activated cultures amounts to nearly the same as total IgM. There- EMMRICH ET AL.  559 
fore, the selective lack of IgG anti-A-CHO in vitro may suggest distinct differ- 
entiation requirements for anti-A-CHO-producing B cells compared with those 
B cell species which readily produce IgG in vitro. 
As an alternative, instead of lacking in vitro differentiation, anti-A-CHO IgG- 
producing B cells are, perhaps, sequestered in certain lymphoid tissues. If this is 
the correct explanation of our results, we would have to conclude again that the 
switch from IgM to IgG production does not occur with human PBL under our 
culture conditions. Indeed, with two different polyclonal activators (PWM and 
Epstein-Barr virus) as well as with antigenic stimulation of human PBL, virtually 
no or very rare switch events from IgM to IgG could be demonstrated in vitro 
(25, 37). This is in sharp contrast to similar experiments in lipopolysaccharide- 
stimulated murine spleen cells (38). As discussed by Yarchoan et al. (25), either 
an intrinsic difference between human and murine B cells or a difference between 
peripheral blood B cells and those of other lymphoid organs might explain the 
results.  Preliminary results with polyclonally activated human spleen cells and 
with tonsilar lymphocytes showed only slightly increased levels of anti-A-CHO 
IgG (F. Emmrich, unpublished data). 
In the control cultures of donor CMR (data not shown) without mitogen or 
streptococcal antigen, the IgM anti-A-CHO  ratio (0.33%) was far less than in 
both antigen-activated (21.3 %) or PWM-activated cultures (10.3 %, see Table I). 
This indicates preferential antibody production in the control cultures by non- 
anti-A-CHO B cells either preactivated in vivo or stimulated by FCS components 
in vitro. As demonstrated in Table III, low IgM anti-A-CHO proportions could 
be elevated by either antigen activation, mitogen activation, or even by increasing 
the cell density. By these procedures, IgM anti-A-CHO proportions of ~15% 
were  reached,  which  are  equal  to  the  precursor  frequency  of polyclonally 
activated B  cells,  as  well as to  the  IgM  anti-A-CHO  proportion  in  serum of 
donor MSS. Together with the other features mentioned above, this finding may 
argue for distinct activation requirements of IgM anti-A-CHO B cells, compared 
with other B cells. A  similar situation has previously been described for mice: 
unresponsiveness to polysaccharide antigens, determined by the xid gene (39), is 
associated with the lack of a B cell subpopulation bearing the Lyb-5 marker (40), 
as  well  as  depressed  IgM  and  IgG3  levels  (41).  Lyb-5  +  B  cells  are  readily 
responsive to  the combination of antigen and soluble helper factors, whereas 
Lyb-5- cells  require  an  MHC-restricted interaction  with  helper  T  cells  (42). 
Hence, human B cells with specificity to A-CHO may be useful for the charac- 
terization of a similar human B cell subpopulation. 
Summary 
The immune response to the group-specific carbohydrate of group A strepto- 
cocci (A-CHO) provides an informative in vitro model for the investigation of 
several aspects of human anticarbohydrate immune responses. A-CHO-specific 
B cells can be polyclonally activated by pokeweed mitogen (PWM), and, specifi- 
cally, by  in  vitro  immunization  with  streptococcal  vaccine.  High  levels of A- 
CHO-specific antibodies, mainly directed to the immunodominant side chain N- 
acetyl-D-glucosamine (GIcNAc), occur in healthy adult individuals. Serum anti- 
body levels are reflected in high frequencies of precursor B cells among periph- 560  HUMAN  IMMUNE  RESPONSE  TO  A-CHO 
eral blood lymphocytes. In one particular case, >15% of all B cells activated by 
PWM for IgM production were found to produce IgM anti-A-CHO antibodies, 
as  determined  in  limiting  dilution  experiments,  as  well  as  by  analyzing  Ig 
concentrations in bulk culture experiments. The case with the lowest proportion 
observed  had  0.3%  A-CHO-specific  B  cells  among  IgM-producing  B  cells. 
Preferential PWM  activation of anti-A-CHO-producing B  cells could be  ex- 
cluded. 
The comparison of the proportions of anti-A-CHO IgM produced in vivo, 
and of B cells producing antibodies of this specificity in peripheral blood, suggests 
a  similar distribution of specific precursor  B  cells  in  the antibody-producing 
lymphoid tissue  compartments and  in  peripheral  blood.  However,  nearly all 
specific antibodies produced in vitro belong to the  IgM isotype, whereas IgG 
anti-A-CHO in  high amounts, mostly exceeding the specific IgM, was  found 
only among anti-A-CHO antibodies produced in vivo. Low anti-A-CHO IgG 
production  was  seen  in  polyclonally activated as  well  as  in  antigen-activated 
cultures, whereas, in contrast, total IgG was produced in considerable amounts 
after polyclonal activation. This suggests a different distribution pattern, and]or 
diverse differentiation requirements for anti-A-CHO-producing B cells,  com- 
pared with other B cell species. 
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